Cited 5 times in
Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김명수 | - |
dc.contributor.author | 이재근 | - |
dc.date.accessioned | 2022-09-06T06:41:43Z | - |
dc.date.available | 2022-09-06T06:41:43Z | - |
dc.date.issued | 2020-02 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/190268 | - |
dc.description.abstract | Background: Prophylaxis for hepatitis B virus (HBV) recurrence is essential after liver transplantation (LT) in HBV-associated recipients. We conducted real-world analysis of HBV prophylaxis after LT in the Korean population. Methods: Korean Organ Transplantation Registry (KOTRY) database and additionally collected data (n = 326) were analyzed with special reference to types of HBV prophylaxis. Results: The study cohort comprised 267 cases of living-donor LT and 59 cases of deceased-donor LT. Hepatocellular carcinoma (HCC) was diagnosed in 232 (71.2%) of these subjects. Antiviral agents were used in 255 patients (78.2%) prior to LT. HBV DNA was undetectable in 69 cases (21.2%) and detectable over wide concentrations in the other 257 patients (78.8%) prior to LT. Polymerase chain reaction analysis of the store blood samples detected HBV DNA in all patients, with 159 patients (48.9%) showing concentrations > 100 IU/mL. Post-transplant HBV regimens during the first year included combination therapy in 196 (60.1%), hepatitis B immunoglobulin (HBIG) monotherapy in 121 (37.1%), and antiviral monotherapy in 9 (2.8%). In the second post-transplant year, these regimens had changed to combination therapy in 187 (57.4%), HBIG monotherapy in 112 (34.4%), and antiviral monotherapy in 27 (8.3%). Trough antibody to hepatitis B surface antigen titers > 500 IU/mL and >1,000 IU/mL were observed in 61.7% and 25.2%, respectively. The mean simulative half-life of HBIG was 21.6 +/- 4.3 days with a median 17.7 days. Up to 2-year follow-up period, HCC recurrence and HBV recurrence developed in 18 (5.5%) and 6 (1.8%), respectively. HCC recurrence developed in 3 of 6 patients with HBV recurrence. Conclusion: Combination therapy is the mainstay of HBV prophylaxis protocols in a majority of Korean LT centers, but HBIG was often administered excessively. Individualized optimization of HBIG treatments using SHL is necessary to adjust the HBIG infusion interval. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | 대한의학회(The Korean Academy of Medical Sciences) | - |
dc.relation.isPartOf | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antiviral Agents* / therapeutic use | - |
dc.subject.MESH | Cohort Studies | - |
dc.subject.MESH | DNA, Viral / blood | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Hepatitis B Surface Antigens / blood | - |
dc.subject.MESH | Hepatitis B virus* / genetics | - |
dc.subject.MESH | Hepatitis B* / prevention & control | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunoglobulins* / therapeutic use | - |
dc.subject.MESH | Liver Transplantation* | - |
dc.subject.MESH | Living Donors* | - |
dc.subject.MESH | Registries | - |
dc.subject.MESH | Republic of Korea | - |
dc.title | Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Gil Chun Park | - |
dc.contributor.googleauthor | Shin Hwang | - |
dc.contributor.googleauthor | Myoung Soo Kim | - |
dc.contributor.googleauthor | Dong Hwan Jung | - |
dc.contributor.googleauthor | Gi Won Song | - |
dc.contributor.googleauthor | Kwang Woong Lee | - |
dc.contributor.googleauthor | Jong Man Kim | - |
dc.contributor.googleauthor | Jae Geun Lee | - |
dc.contributor.googleauthor | Je Ho Ryu | - |
dc.contributor.googleauthor | Dong Lak Choi | - |
dc.contributor.googleauthor | Hee Jung Wang | - |
dc.contributor.googleauthor | Bong Wan Kim | - |
dc.contributor.googleauthor | Dong Sik Kim | - |
dc.contributor.googleauthor | Yang Won Nah | - |
dc.contributor.googleauthor | Young Kyoung You | - |
dc.contributor.googleauthor | Koo Jeong Kang | - |
dc.contributor.googleauthor | Hee Chul Yu | - |
dc.contributor.googleauthor | Yo Han Park | - |
dc.contributor.googleauthor | Kyung Jin Lee | - |
dc.contributor.googleauthor | Yun Kyu Kim | - |
dc.identifier.doi | 10.3346/jkms.2020.35.e36 | - |
dc.contributor.localId | A00424 | - |
dc.contributor.localId | A03068 | - |
dc.relation.journalcode | J01517 | - |
dc.identifier.eissn | 1598-6357 | - |
dc.identifier.pmid | 32056398 | - |
dc.subject.keyword | Hepatitis B Virus | - |
dc.subject.keyword | Recurrence | - |
dc.subject.keyword | Liver Transplantation | - |
dc.subject.keyword | Hepatitis B Immunoglobulin | - |
dc.subject.keyword | Antiviral Agent | - |
dc.contributor.alternativeName | Kim, Myoung Soo | - |
dc.contributor.affiliatedAuthor | 김명수 | - |
dc.contributor.affiliatedAuthor | 이재근 | - |
dc.citation.volume | 35 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | e36 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, Vol.35(6) : e36, 2020-02 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.